A comparison of 67CU production by proton (67 TO 12 MEV) induced reactions on NATZN and on enriched 68ZN/70ZN

Schwarzbach, R.; Zimmermann, Kurt; Novak‐Hofer, Ilse; Schubiger, P. August

doi:10.1002/jlcr.25804401284

Cited by 9 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of high yields of 64 Cu ( 68 Zn via p,2p reaction) being the greatest challenge as its elimination requires its decay before the 67 Cu can be utilised. In an effort to avoid the production of 64 Cu, low energy protons (<25 MeV) on enriched 70 Zn have also been investigated for the production of 67 Cu, however, the yields from this path are comparatively low [56,60]. A further complicating feature in the production of copper isotopes is the presence of contaminating natural copper in the zinc targets, production apparatus and solutions that often result in the reduction of the specific activity (i.e., ratio radioactive copper/non-radioactive copper) of the final product.…”

Section: Production Of 67 Cu and 64 Cumentioning

confidence: 99%

“…Cu-67 can be produced, by bombardment, of 67 Zn with neutrons in high flux reactors [47,[52][53][54][55] or using alpha particles on Ni or high energy protons (P60 MeV) on Zn (natural or enriched 68 Zn) [48,49,[56][57][58][59][60]. The worldwide availability of 67 Cu has suffered from irregular supply, limited production yields and radioisotope contaminants ( 62 Zn, 67 Ga, 65 Zn, 55 Co, 58 Co, 64 Cu and 57 Ni).…”

Section: Production Of 67 Cu and 64 Cumentioning

confidence: 99%

See 1 more Smart Citation

Molecular imaging with copper-64

Smith

2004

Journal of Inorganic Biochemistry

210

161

View full text Add to dashboard Cite

Section: Production Of 67 Cu and 64 Cumentioning

confidence: 99%

Section: Production Of 67 Cu and 64 Cumentioning

confidence: 99%

Molecular imaging with copper-64

Smith

2004

Journal of Inorganic Biochemistry

210

161

View full text Add to dashboard Cite

“…The system can, however, still be put to good use towards the development of novel, non-standard radiometals. Previously, the station was used to produce the likes of 18 F [15] and 124 I [16] in a novel way by utilizing its higher beam energy, as well as 67 Cu, [17][18][19] 82 Sr, 52 Fe, [20] 76 Br [21] and 68 Ge, but these activities were halted well over a decade ago. With the increased popularity of PET for the diagnosis of cancer, as a result of its superior image resolution over Single Photon Emission Computed Tomography (SPECT), the strategy of the station's use was adjusted to meet the growing demand for new positron-emitting radionuclides.…”

Section: Injector II and The Ip2 Irradiation Stationmentioning

confidence: 99%

“…Much development work was performed at PSI towards the production of 18 F, [13] seen today as the gold standard for PET imaging. The radionuclide is, arguably, the most common available today, as it is easily produced at medical cyclotrons utilizing the 18 O(p,n) 18 F nuclear reaction. This production route was developed using a water target constructed of silver, with an internal volume of 2.6 mL (Fig.…”

Section: Fmentioning

confidence: 99%

The Metamorphosis of Radionuclide Production and Development at Paul Scherrer Institute

Grundler

Eichler

Talip

et al. 2020

Chimia

Self Cite

View full text Add to dashboard Cite

Radionuclide production and development has a long history at the Paul Scherrer Institute (PSI) and dates back to the founding times of its forerunner institutions: the Federal Institute for Reactor Research and the Swiss Institute for Nuclear Research. The facilities used for this purpose have evolved substantially over the last five decades. Many radiometals in use today, as radiopharmaceuticals, are for the diagnosis and treatment of disease, with the most popular means of detection being Positron Emission Tomography. These positron emitters are easily produced at low proton energies using medical cyclotrons, however, developments at these facilities are lacking. Currently, the fixed 72 MeV proton beam at PSI is degraded at IP2 irradiation station to provide the desired energy to irradiate targets to produce the likes of 44Sc, 43Sc and 64Cu as a proof of principle, which are of great interest to the nuclear medicine community. This development work can then be implemented at facilities containing medical cyclotrons. A history of the development of radionuclides at PSI, along with current development and projects with partner institutions, is described.

show abstract

“…The high cost of the 70 Zn target makes its use impractical, however. Using a 68 Zn target, which can be recycled, will allow the production of about 17 GBq of 67 Cu, which is sufficient for achieving several therapeutic doses of antibody, envisaging 2.2 GBq (60 mCi) as the highest dose level [6].…”

Section: Production Of 67 Cumentioning

confidence: 99%

Copper-67 as a therapeutic nuclide for radioimmunotherapy

2002

View full text Add to dashboard Cite

The application of the beta particle-emitting nuclide 67Cu in radioimmunotherapy is reviewed. The production of the nuclide is outlined, and different production modes are discussed with an emphasis on cyclotron production. A short survey of copper chelators currently used for antibody labelling and their impact on the pharmacokinetics of 67Cu-labelled immunoconjugates is provided. Protocols for antibody labelling with 67Cu as well as quality control procedures for 67Cu-labelled antibodies are described. Preclinical data on the biological properties of 67Cu-labelled immunoconjugates are reported and discussed. 67Cu-labelled antibodies show higher and more persistent tumour uptake than their radioiodinated counterparts due to accumulation of labelled metabolites in tumour cells. Biodistribution of 67Cu-labelled antibody fragments has been improved by selection of negatively charged chelators and peptide linkers. Pharmacokinetic analysis of the accumulated dose in tumour and critical organs such as the kidney and liver indicates that, despite this improvement, intact 67Cu-labelled antibodies achieve higher tumour uptake and better therapeutic ratios than 67Cu-labelled antibody fragments and that they are at present the logical choice for clinical studies. Clinical studies using 67Cu-labelled antibodies in lymphoma, colon carcinoma and bladder cancer patients are reviewed. Some of the advantages over radioiodinated antibodies found in the preclinical work, such as higher tumour uptake and better tumour/blood ratios, have also been found with systemic application in lymphoma and colon carcinoma. However, in both lymphoma and colon carcinoma patients, the radiation dose to the liver has been found to be higher from 67Cu- than from 131I-labelled antibodies. The intravesical application of 67Cu-labelled antibody has been shown to be a promising approach for targetting cytotoxic radiation to superficial bladder tumours, without detectable systemic absorption. Given the favourable properties of 67Cu-labelled antibodies, it is the reliable availability of the 67Cu nuclide which is the limiting factor for their more widespread evaluation in radioimmunotherapy trials.

show abstract

A comparison of ⁶⁷CU production by proton (67 TO 12 MEV) induced reactions on ^NATZN and on enriched ⁶⁸ZN/⁷⁰ZN

Abstract: Sjmposium Abstracts. S809 68Zn: 0.03% 6jZn, 0.09 % 66Zn, 0.75% 67Zn ,98,32% 68Zn, 0.81% 70Zn 70Zn: 0.07% -Zn ,0.006% 66Zn , 0.01% 67Zn , 6.06% 68Zn ,93.92% "Zn "".Zn: 48.6% @Zn , 27.9% 66Zn , 4.1% 67Zn , 18.8% 68Zn , 0.6% 70Zn .

Cited by 9 publications

References 6 publications

Molecular imaging with copper-64

Molecular imaging with copper-64

The Metamorphosis of Radionuclide Production and Development at Paul Scherrer Institute

Copper-67 as a therapeutic nuclide for radioimmunotherapy

Contact Info

Product

Resources

About